LY4086940

LY4086940 is an investigational oral weight-loss drug from Eli Lilly. Lilly’s investor slides list its first trial under the program name “GGG Tri-Agonist III,” and a separate slide describes an oral GGG peptide acting on GLP-1, GIP and glucagon receptors. Lilly has not confirmed that these are the same thing or published a structure. A 219-person phase 1 trial has finished, a 460-person phase 2 trial is registered, and no doses have been disclosed.

Research snapshot

Peptide category	Reported GLP-1, GIP and glucagon receptor triple agonist (Lilly program name “GGG Tri-Agonist III”); structure not published
Primary research interest	Weight management in adults with obesity or overweight
Highest available evidence	Registered human trials without published results
Human research available	Yes. One completed phase 1 trial (219 participants, no results posted) and one phase 2 trial registered but not yet recruiting
Development status	Phase 1 completed August 5, 2026; phase 2 listed to begin November 2026
Regulatory status	Not approved anywhere

Technical identity

Primary name	LY4086940
Alternative names	GGG Tri-Agonist III (Lilly’s program name in investor slides); spelling variants LY-4086940 and LY 4086940
Peptide sequence	Not published
Amino-acid length	Not reliably established
Molecular formula	Not reliably established
Molecular weight	Not reliably established
CAS Registry Number	Not reliably established
PubChem CID	Not reliably established
UNII	Not reliably established
DrugBank ID	Not listed
Chemical modifications	Not disclosed
Peptide class	Reported oral triple (GLP-1, GIP, glucagon) agonist; peptide status comes from slide labeling and is not confirmed for LY4086940
Primary biological target	GLP-1, GIP and glucagon receptors (reported, not confirmed for this compound)
Developer or originator	Eli Lilly and Company
Development status	Phase 1 completed; phase 2 registered, not yet recruiting

What is LY4086940?

LY4086940 is a development code for an experimental drug that Eli Lilly is testing for weight management. Both registered trials give it by mouth, apart from one open-label part of the first study that used a single intravenous dose. Lilly has not published what the molecule is. There is no disclosed sequence, formula, molecular weight or registry number, and the trial records describe the drug only by its code.

What Lilly does say publicly comes from investor material. In its fourth-quarter 2025 earnings slides, presented on the February 4, 2026 call, the pipeline chart lists a program called “GGG Tri-Agonist III,” and the early-phase trials table puts that program name on the phase 1 study titled as a trial of LY4086940. The third-quarter 2025 slides, presented on the October 30, 2025 call, show the same row with 165 patients, where the later deck shows 201 and the registry now shows 219 enrolled. Lilly’s 2025 ADA investor presentation separately shows an “oral GGG peptide” labeled as a GLP-1, GIP and glucagon agonist, the same label it gives retatrutide. None of those slides says in so many words that the oral GGG peptide and LY4086940 are the same compound.

That points to an oral drug in the triple-agonist family, the same three-receptor idea behind retatrutide, delivered as a pill instead of an injection. It is a working picture and not a confirmed one. Lilly’s patent filings on GIP/GLP-1/glucagon tri-receptor agonists, WO2024163535A1 and its US counterpart, include peptide examples and oral-delivery work, but no public document ties a specific example to LY4086940. Our LY4086940 structure and sequence write-up goes through each document and what it can and cannot establish.

The first real test of weight loss is the phase 2 trial Lilly registered in October 2026. It randomizes adults without diabetes to one of six dose levels, some with different titration schedules, or to placebo, and measures body weight at 32 and 48 weeks. Until those results exist, every statement about how well LY4086940 works is a prediction. Both registry records are listed in the clinical trial tracker, and the same trials are covered on The Weight Loss Atlas LY4086940 page and Eloralintide Research’s LY4086940 trial records page. The dated sequence of what Lilly has said publicly is laid out in the LY4086940 timeline. Lilly’s other obesity and diabetes programs are tracked in the Eli Lilly tracker.

How does it work?

Plain-English explanation

After you eat, your gut releases hormones that tell your brain you are full, slow the stomach and help the pancreas handle blood sugar. GLP-1 and GIP are two of them. Glucagon is a third hormone that is thought to raise energy burning and change how the liver handles fat. Semaglutide copies GLP-1. Tirzepatide copies GLP-1 and GIP. retatrutide copies all three. Lilly’s “GGG” label suggests LY4086940 follows the same three-target design. That is an inference from a program name and a slide label, since Lilly has not published receptor data for this compound.

Technical explanation

Both the program name “GGG Tri-Agonist III” and the “oral GGG peptide” slide label point to agonism at the GLP-1 receptor, the GIP receptor and the glucagon receptor. No binding, potency or selectivity data for LY4086940 are public, so the balance between the three receptors is unknown. Half-life and absorption figures are also unpublished. The phase 1 trial lists peak drug concentration (Cmax) and total exposure over time (AUC) as secondary outcomes, measured from before the dose through day 64, so Lilly holds those numbers, but no results are posted. If LY4086940 is a peptide, taking it by mouth is a hard problem, because stomach acid and digestive enzymes break peptides down and they cross the gut wall poorly. How Lilly handles that for this compound has not been disclosed.

Potential benefits and research applications

Weight reduction in obesity or overweight

Weight loss is the only efficacy question the registry records ask. The phase 2 trial’s primary outcome is the percent change in body weight from baseline to week 32, with the same measure at week 48 as a secondary outcome, along with a quality-of-life questionnaire and drug levels at steady state. It is set to enroll adults aged 18 to 75 who have obesity, or overweight plus a weight-related health condition, and no diabetes. No weight-loss result for LY4086940 has been published or presented, so any benefit claim today is a hypothesis built on what related triple agonists have done. Evidence level: registered human trial without results.

Type 2 diabetes

Part D of the phase 1 trial gave LY4086940 for 4 to 6 weeks to adults with type 2 diabetes and overweight or obesity, with an HbA1c between 6.5 and 10.5 percent. Its registered primary outcome is safety, not blood sugar, and no results are posted. Whether LY4086940 improves glucose control has not been established.

What dosage information circulates?

Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate. No dose amount for LY4086940 has been disclosed in either registered trial, in Lilly’s investor slides or in Lilly’s patent publications.

Reported use or research objective	Route reported	Amount reported	Frequency reported	Reported duration	Evidence or source category
Phase 1 safety and pharmacokinetics (NCT06945419)	Oral (Parts A to D); intravenous (Part E)	Not disclosed; the registry lists no amounts	Single dose (Part A) or repeated dosing; interval not stated	Single dose; 3 days; 4 weeks (Parts B and C); 4 to 6 weeks (Part D)	Registered but unpublished human trial
Phase 2 weight management (NCT07890376)	Oral	Not disclosed; six dose levels (Dose 1 to Dose 6) are named with no amounts	Not stated; Dose 3 has two titration schedules and Dose 6 has three	About 58 weeks per participant; primary weight outcome at week 32	Registered but unpublished human trial (not yet recruiting)
Practitioner or community protocols	Not applicable	Not applicable	Not applicable	Not applicable	Not consistently reported; no established or reliably sourced dosing information exists

There is nothing to reconcile, because no amount exists in the public record. What the registry does show is structure: the phase 2 trial has nine LY4086940 arms covering six dose levels, plus a placebo arm. Titration means starting at a lower amount and stepping up over time. The registry uses the term but gives no schedule, no milligram amounts and no dosing interval.

No dose for LY4086940 is widely repeated online, so there is no unsourced figure to trace. If a number for this compound appears on a forum or a sales page, it has no identifiable origin and should be regarded as unverified. Weight-based dosing is not mentioned in either record, and no animal data have been published, so there is nothing to convert. No established or reliably sourced dosing information was identified. That will change if Lilly posts the phase 1 results or presents them at a scientific meeting.

Side effects, risks, and limitations

No safety results for LY4086940 have been published. The phase 1 primary outcome counts participants with a serious adverse event related to the study drug through week 9, and the registry has no results posted, so no adverse-event rate, tolerability finding or dropout number is public. Because the drug is reported to act on GLP-1, GIP and glucagon receptors, the effects reported with related drugs are the ones to watch: nausea, vomiting, diarrhea and constipation with GLP-1 and GIP drugs, and heart-rate changes with other glucagon-receptor agonists. That expectation comes from the drug class, not from LY4086940 data. The retatrutide page shows how those effects have looked in published trials.

The phase 2 exclusion criteria hint at the precautions Lilly is taking: no history of type 1 or type 2 diabetes, no heart attack, stroke, unstable angina or heart-failure hospitalization in the prior six months, and no personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, a standard screen for this drug class.

Identity is the other risk. Because no structure has been published, there is nothing for a laboratory to match a sample against. A vial or capsule labeled LY4086940 outside Lilly’s trials cannot be verified as that compound, and no purity, dose or sterility claim attached to it can be checked. Long-term effects are unknown for the same reason: the longest exposure in the registered trials so far is 4 to 6 weeks in phase 1, and the phase 2 trial would extend that to about 58 weeks per participant.

Regulatory and developmental status

LY4086940 is not approved anywhere, and Lilly has announced no regulatory filing. A third-party tracker of China’s drug regulator lists nine LY4086940 tablet applications accepted on October 30, 2026. That is an unconfirmed secondary report (see the timeline), and acceptance of a filing is not approval. The phase 1 trial (NCT06945419) started April 23, 2025, finished August 5, 2026 and enrolled 219 people at sites in Florida, Texas and Singapore. No results are posted. The phase 2 trial (NCT07890376) was first posted October 22, 2026 and is listed as not yet recruiting. It is estimated to start in November 2026, finish primary data collection in January 2028 and complete in June 2028, with 460 planned participants at sites in the United States and Argentina. It runs under Lilly’s master protocol W8M-MC-CWMM. Follow changes to both records in the trial changes feed.

Frequently asked questions

What is LY4086940?

An investigational oral drug from Eli Lilly being developed for weight management. Lilly lists its program as “GGG Tri-Agonist III.” It has finished a phase 1 safety trial and has a phase 2 weight-loss trial registered. It is not approved anywhere.

What is GGG Tri-Agonist III?

It is the program name Lilly uses in its earnings slides for the study titled as a trial of LY4086940. The “GGG” points to three receptor targets, GLP-1, GIP and glucagon. It is a company program label, not a drug name or a chemical name.

Is LY4086940 a peptide?

Not confirmed. Lilly’s slides describe an “oral GGG peptide,” and its patents on tri-receptor agonists include peptide examples, but no document links either one to LY4086940 by name. Until Lilly publishes a structure, the answer stays open.

How does LY4086940 work?

It is reported to activate GLP-1, GIP and glucagon receptors together, the same three-receptor approach as retatrutide, but in an oral form. Lilly has not published receptor data for this compound, so that mechanism is inferred and not confirmed.

What dosage of LY4086940 has been studied?

Lilly has not disclosed any. The phase 1 trial gave single and repeated oral doses for up to 4 to 6 weeks, plus a single intravenous dose in one part. The phase 2 trial lists six dose levels. No amounts are published in either record.

What dosage commonly circulates online?

No established or reliably sourced dosing information was identified. No figure for LY4086940 is widely repeated online, and any number found without a named source should be regarded as unverified.

Has LY4086940 been studied in humans?

Yes. The phase 1 trial (NCT06945419) enrolled 219 people, ran from April 2025 to August 2026 and has no posted results. A phase 2 trial (NCT07890376) with 460 planned participants is registered and not yet recruiting.

Is LY4086940 approved?

No. It is not approved anywhere, and Lilly has announced no regulatory filing. A third-party tracker reports LY4086940 tablet applications accepted in China on October 30, 2026, which is unconfirmed.

Does LY4086940 have a brand name?

No brand name has been announced for LY4086940. Eli Lilly holds live US trademark applications for Retzoundi, Retkouro and Senmounto, all filed on April 23, 2024, but the USPTO records name no medicine, so nothing in them ties any of the three to LY4086940 or to any other compound. Our Retzoundi and Retkouro write-up shows what the filings say and what they leave out.

How does LY4086940 compare with retatrutide and orforglipron?

Retatrutide is Lilly’s injectable GLP-1, GIP and glucagon triple agonist, with published phase 3 results. Orforglipron is an oral GLP-1 drug that is a small molecule and not a peptide. NBIP-1968 from Neurocrine is another coded triple agonist, at phase 1 as a weekly injection. LY4086940 is reported to combine the oral route with the triple-agonist idea, but it has no published efficacy or safety data yet. You can also line them up in the compare tool.

What remains unknown?

Almost everything that matters: the structure, the balance between the three receptors, the dose amounts, whether the oral route delivers enough drug, how much weight people lose and how well they tolerate it. The phase 1 results and the phase 2 readout are the next sources of answers.

Bottom line

LY4086940 is interesting because it appears to pair the three-receptor approach of retatrutide with an oral route. The strongest evidence available is two registry records from Lilly, a completed phase 1 trial with 219 participants and a registered phase 2 trial with 460 planned, plus investor slides that connect the program name “GGG Tri-Agonist III” to the study. No dosing has been published: neither record lists an amount, and no community protocol with an identifiable source was found. The triple-agonist mechanism, the peptide classification and any weight-loss benefit remain unconfirmed, and no efficacy or safety result has been released. The compound is not approved anywhere, and phase 2 is listed to begin in November 2026.